Blue Horseshoe Stocks

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug. To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: LLY Options Recap & More

Eli Lilly and Co. LLY – Options Update

In our premarket report on Friday morning, we finished off with a set of fresh options ideas for the LLY chain, and were met with nice gain opportunities on the day on all accounts.

In addition to a daytrading idea with the LLY Weekly $72 and $72.50 Calls, which worked out in spades, we also got some really good initial movement out of the longer term target we put forth, the 01/20 $75 Calls.

Weekly $72 Calls – Range: .20-1.25 – Max Gain: 475%
Weekly $72.50 Calls – Range: .15-.80 – Max Gain: 433%
1/20 $75 Calls – Range: .77-1.39 – Max Gain: 81%

We offer congratulations to anyone who benefited from the short-term ideas, and we’ll be sure to stay on the trail of those 01/20 $75 Calls in the weeks ahead.

Globalstar, Inc. GSAT

We caught a glimpse of GSAT on our scanner this morning and feel it’s worthy of mentioning, based on a number of factors. Last week, the moves that the stock had been making off of its recent relative lows in the low .70-range began to increase.

On Thursday, the stock bullishly breached its 50DMA, culminating in a huge spike in volume on Friday. Roughly six times the monthly average trading volume accompanied a break of the dollar mark. We’re going to put this on watch as a possible momentum play.

AmpliPhi BioSciences, Inc. APHB

Speaking of bottom-bouncers, APHB cropped on our scan as well, and it has a look of high potential as it’s coming up off of its recently established annual lows.

In addition, there’s a gap to fill on the chart to the upside, and with the stock already trading up in the premarket, that’s a real possibility here. With such a ripe chart, we’ll be very interested to follow APHB’s activity out of the gate this morning.

Extended Watchlist:
NHMD, ECPN, EVOK, APTO, ANY(Bottom Play)

Blue Horseshoe Stocks: Shipping Watchlist & More

Shipping Sector Watchlist

Earlier this fall, we found an incredible amount of success within the shipping sector, as an industry-wide wave of bullish activity carried many related stocks to record moves.

That rush tuckered out a few weeks back, but we want to circle back around this morning to cast a light on several of these stocks that we think could be gearing up for a recovery. Each of the following had been in a drastic downturn leading into yesterday’s session, and each of them began to show some major signs of life in coming off their bottoms.

We’ll want to keep all of them in mind in coming sessions, and watch for signs that a more sustained uptrend could take effect.

Dry Ships, Inc. DRYS

Sino-Global Shipping America, Ltd. SINO

Diana Containerships, Inc. DCIX

Diana Shipping, Inc. DSX

Seanergy Maritime Holdings Corp. SHIP

Euroseas Ltd. ESEA

Global Ship Lease, Inc. GSL

Catalyst Biosciences, Inc. CBIO

We stipulated yesterday that if CBIO held above .80 on any early pullbacks, that we’d be interested in tracking its activity through the session, and it did just that.

The intraday machinations of the stock actually provided two separate opportunties for swing trades. First, the initial run out of the gate that took it from 1.12-1.42 (+27%) and a subsequent dip-and-rip pattern from .855 back to 1.12 later on in the day (+31%).

With volatility sufficient to provide over 50% in cumulative gains on the day, and the fact that it maintained support above our designated level, we’ll keep CBIO on our radar for the time being.

Eli Lilly and Co. LLY

On strong 2017 guidance released this week, LLY beat Wall Street’s forecast outlook estimates for the first time in 3 years. As a result, the stock started to climb, and has begun to fill a large gap on the chart to the upside.

What we want to do here is highlight both a short term and extended term options trading idea to correspond with the present situation. For swing trades this week, we’ll look at the LLY Weekly $72 and $72.50 Calls, and to take advantage of the possibility of an extended uptrend, the LLY 01/20 $75 Calls.

Extended Watchlist:
LSCG, TRUU, ERFB, TTCM, AIRW, NDEV, AXPW

Blue Horseshoe Stocks: IDXG Update & More

Interpace Diagnostics Group, Inc. IDXG

We tracked IDXG last week over a couple of stellar sessions that led to a swing of more than 400%, cautioning that a dip-and-rip could be in the cards after seeing such a volatile move to the upside.

That’s exactly what we’ve seen in the past couple of days, as IDXG came down to find support at the .865 level, and in the ensuing three sessions it’s been steadily registering higher highs and higher lows, getting back to 1.25 yesterday (+45%).

We’ll continue to follow this story, which kicked off with the revelation that Aetna would cover Interpace’s ThyraMir™ test for its 46 million insured members. (>>View PR)

Experience Art & Design, Inc. EXAD

We had EXAD tagged in yesterday’s premarket report and this subpenny play produced a moderate run to kick off the session, even as the larger markets were struggling with the Fed rate hike announcement.

From an early low of .0023, the stock took just the first hour of trading to find its way up to a high of .0038, for a 65% pop. IDXG hung around that level until around lunchtime, and it did come back down to its daily low toward the close, so we’ll be looking for the possibility of a rebound.

Catalyst Biosciences, Inc. CBIO

We’re also interested in following the activity of CBIO today, which is gapping up in the premarket to the tune of more than 100% and looks like it could be lining up to have a big day. We’ll want to make sure it holds above its 50DMA (.80) on any pullbacks, but if it can breach past its 200DMA of 1.31, things could get very interesting.

News broke yesterday via an 8-K filing that CBIO had entered into a definitive agreement with Wyeth LLC, (wholly-owned subsidiary of Pfizer Inc.) to transfer exclusive rights to research, develop, manufacture and commercialize Factor VIIa variants, CB 813a and CB 813d, as well as transferring the investigational NDA to CBIO as well. (>>View Filing)

Fresh Options Idea: Transocean, Inc. RIG $15 and $14.50 Puts

Extended Watchlist:
VCEL, NWBO, BCLI, BPMX, DLOV, PPMT

Blue Horseshoe Stocks: QFOR, NDEV Updates & More

Quadrant 4 Systems Corp. QFOR

Yesterday marked the first time we ever mentioned QFOR in any of our premarket reports, and in a stroke of fantastic timing, the stock made one heck of a debut for us.

We were interested because we noticed that after taking a huge beating from nearly .20 at the beginning of the month, the stock finally started to show some signs of life, trending off of its lows on Monday.

That momentum helped facilitate yesterday’s run from a low of .04175 to .0712, which worked out to a healthy intraday pop of 80% on more than twice the monthly average volume. We want to continue to monitor this as a recovery play, as the regaining of even a portion of the ground that it lost in recent weeks would represent significant gains from the present juncture.

Cellectar Biosciences, Inc. CLRB

Speaking of bottom plays, there’s another one hitting our scanners this morning in CLRB. This stock found new 6-month lows yesterday, and from a technical standpoint, this is what can only be referred to as an incredibly ripe chart.

We’ve included a snapshot below, and as you can see, it currently boasts many of the characteristics that we constantly watch for, and often benefit from. Trading at recent relative lows, with an RSI indicating oversold, the MACD converging toward an impending bullish cross, and a sizable gap to the upside.

It’s for these reasons that CLRB must be afforded a spot on our watch-screens as we cruise through midweek.

Novus Acquisition & Development Corp. NDEV

After tagging NDEV in Monday’s morning report and witnessing a nice initial move from .30-.442 (+47%), we followed up yesterday and cautioned that a continuation of momentum made it necessary to stay on its trail, and we’re glad we did.

The stock produced a second straight solid session for us, running from its morning low of .43 to a new high of .559, a intraday pop of 30% and a two-day increase amounting to 86% High volume to the tune of more than five times its monthly average, and another strong close will keep NDEV’s slot on our radar safe for the time being.

Extended Watchlist:
ACAU, DTEA, ECTE, EXAD, PGUS, PLX(Bottom-Bouncer)